Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 3/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837207 | 0.90 | CYP3A4 (0.44) | CYP3A4CYP2C9KCNH2CA2CA9 | |
| SCHEMBL4839501 | 0.82 | L3MBTL1 (0.49) | CYP3A4CYP2C9KCNH2CA2CA9 | |
| SCHEMBL4835594 | 0.82 | CYP3A4 (0.47) | KMT2ACYP3A4CYP2C9KCNH2CA2 | |
| SCHEMBL4831283 | 0.80 | CA2 (0.49) | KMT2ACYP3A4CYP2C9KCNH2CA2 | |
| SCHEMBL4838181 | 0.80 | CYP3A4 (0.36) | CYP3A4CYP2C9KCNH2CA2CA9 | |
| SCHEMBL4840448 | 0.80 | L3MBTL1 (0.43) | CYP3A4CYP2C9KCNH2CA2CA9 | |
| SCHEMBL4838164 | 0.80 | NPC1 (0.48) | KMT2ACYP2C9CA2CA9L3MBTL1 | |
| SCHEMBL4886128 | 0.79 | KMT2A (0.45) | KMT2ACYP2C9CA2CA9USP2 | |
| SCHEMBL4839942 | 0.78 | CA2 (0.45) | KMT2ACA2CA9L3MBTL1 | |
| SCHEMBL4840798 | 0.76 | MMP2 (0.45) | CA2CA9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365091-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2008-04-29 | — | — | US | disclosed |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2006-12-21 | — | — | US | disclosed |
| US-7105539-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| EP-1572645-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | Enobia Pharma Inc. (CA) | 2005-09-14 | — | — | EP | disclosed |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | BIOMEP INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004050620-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | ENOBIA PHARMA (CA) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | GLS, SUCNR1, PGD | KMT2A 2453/4885CYP3A4 1480/4885CYP2C9 1090/4885 |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, PGD | KMT2A 2577/4885CYP3A4 1294/4885CYP2C9 940/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | KMT2A 2487/4885CYP3A4 1300/4885CYP2C9 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.